SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

Home・Elenco Azioni・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

181.4 3.54

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

181.4

Massimo

183.3

Metriche Chiave
By Trading Economics
Entrata	41M 88M
Vendite	-11M 762M
P/E Media del settore	62.036 58.051
EPS	1.17
Margine di Profitto	11.569
Dipendenti	10,456
EBITDA	26M 225M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.37% upside

Dividendi
By Dow Jones
Utili prossimi	23 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.6B 17B
Apertura precedente	177.86
Chiusura precedente	181.4

Notizie sul Sentiment di mercato

By Acuity

21%

79%

30 / 438 Classifica in Finance

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 mag 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mag 2026, 20:53 UTC

Utili

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mag 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 20:33 UTC

Discorsi di Mercato

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mag 2026, 20:11 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 19:47 UTC

Utili

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mag 2026, 19:36 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mag 2026, 19:22 UTC

Discorsi di Mercato

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mag 2026, 19:05 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mag 2026, 18:19 UTC

Discorsi di Mercato

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mag 2026, 18:12 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mag 2026, 18:11 UTC

Discorsi di Mercato

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mag 2026, 18:10 UTC

Discorsi di Mercato

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mag 2026, 17:55 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 17:55 UTC

Discorsi di Mercato

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mag 2026, 17:00 UTC

Utili

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

29 mag 2026, 16:02 UTC

Discorsi di Mercato

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mag 2026, 15:40 UTC

Discorsi di Mercato

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mag 2026, 15:20 UTC

Discorsi di Mercato

Canada's Economy Not Looking All That Bright -- Market Talk

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

33.37% in crescita

Previsioni per 12 mesi

Media 233 EUR 33.37%

Alto 262 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

30 / 438 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.